Buy Antibiotics Online

) plan to become a leader in biotech drugs and widen its footprint in emerging markets created plenty of buzz last week, underscoring the importance pharma puts on developing new and better business models.
The nation's No. 2 drug maker unveiled its plan Dec. 9 at its annual business briefing with analysts. Much of the attention centered on Merck's announcement of a new division, Merck BioVentures, that will make new and generic biotech drugs.
The company also said it's on track to reach a goal of $2 billion in annual sales from emerging markets such as Brazil, China and India. Merck eyes more Continue reading

. It's based on a Rand survey of 4,000 U.S. adults that shows the following:
Fifty-three percent of all adults surveyed have no intention of getting the flu vaccine this year, while 17 percent say they haven't yet but will at some point.
Seventy percent of healthy adults under age 50 have no intention of being vaccinated, while 16 percent say they will at some point but haven't yet.
Public-health experts are up in arms, saying that it's a
on our nation's health report card. Yet, I'm not quite sure what the brouhaha is about. After all, the Centers for Disease Control and Prevention
—only Continue reading

The possibility of a merger between Excellus BlueCross and BlueShield and HealthNow New York raises questions about whether such a deal would really be in the best interest of consumers.
Merger talks between the two insurers ended unsuccessfully sometime in the last year, largely due to the sour economy. But the companies remain interested in combining operations and could resume negotiations sometime in the future.
A merger could mean reduced costs for the two companies as they eliminate duplicate functions, lay off unneeded workers and pursue other efficiencies.
But the proposed deal also Continue reading